Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1-based therapy for insulin sensitivity in newly diagnosed obese type 2 diabetes
ChiCTR1900020647Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- Jan 2019
- Modality
- Peptides, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide, metformin and glimepiride in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoints: Muscle microvascular blood flow, Brachial flow-mediated dilatation and 1 more. Started Jan 2019; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR1900020647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020647.